57th ASH Annual Meeting and Exposition (December 5-8, 2015): 703. Adoptive Immunotherapy: Poster I

Adoptive Immunotherapy Oral and Poster Abstracts
Poster

Hall A, Level 2 (Orange County Convention Center)

TNF-Alpha Priming Enhances CD4⁺FoxP3⁺ Regulatory T Cell Suppressive Function in GvHD Prevention and Treatment

Antonio Pierini, M.D.^*, Caitlin Moffett^*, Dominik Schneidawind, M.D.^*, Jeanette Baker, Ph.D.^*, Hidekazu Nishikii, MD, PhD^*, Yuqiong Pan, M.D., Ph.D.^*, Maite Alvarez, Ph.D.^*, Everett Meyer, MD, PhD and Robert S. Negrin, MD

Division of Blood and Marrow Transplantation, Stanford University, Stanford, CA

1886

Inducible MyD88/CD40 Enhances Proliferation and Survival of PRAME-Specific TCR-Engineered T Cells and Increases Anti-Tumor Effects in Myeloma

Tsvetalina Hoang, PhD¹^*, Aaron Foster, PhD¹^*, Jeannette Crisostomo¹^*, An Lu¹^*, Annemarie Moseley, MD, PhD¹^*, Mirjam H.M. Heemskerk, PhD², Kevin M Slawin, MD¹^* and David M Spencer, PhD¹^*

¹Bellicum Pharmaceuticals, Houston, TX
²Dept. of Hematology, LUMC, Leiden, Netherlands

1887

Treatment of Post- HSCT Immunodeficiency By Infusion of Ex Vivo- Generated T Cell Precursors from Adult and Cord Blood Hematopoietic Stem and Progenitor Cells

Laura Simons, MD PhD¹^*, Corinne De La Chappedelaine¹^*, Christian Reimann, MD PhD²^*, Elodie Elkaim, MD¹^*, Sandrine Susini, PhD¹^*, Kuiying Ma¹^*, Fabien Touzot, MD, PhD³^*, Marina Cavazzana, MD, PhD^1,3 and Isabelle Andrè-Schmutz, PhD¹^*

¹IMAGINE Institute, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
²Institute for Cell and Gene Therapy, University Medical Center Freiburg, Freiburg, Germany
³Biotherapy Department, Hôpital Universitaire Necker -Enfants Malades, Paris, France

1888

Fucosylated Antigen-Specific Cytotoxic T Lymphocytes Demonstrate Enhanced Killing of Leukemia Targets

Gheath Alatrash, DO, PhD¹, Mao Zhang, MPH¹^*, Na Qiao, PhD²^*, Pariya Sukhumalchandra, BS¹^*, Madhushree Zope¹^*, Anne V. Philips, PhD²^*, Alexander Perakis, BA¹^*, Lisa St. John, PhD¹^*, Maria R. Khouri¹^*, Victor Gall, MD²^*, Karen C. Dwyer, PhD¹^*, Jodie Polan, MS¹^*, Jeffrey J. Molldrem, MD³, Elizabeth J. Shpall, MD¹ and Elizabeth A. Mittendorf, MD, PhD²^*

¹Department of Stem Cell Transplantation & Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
²Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
³Stem Cell Transplantation and Cellular Therapy, University of Texas M.D. Anderson Cancer Center, Houston, TX

1889

Anti-Human T-Lymphocyte Immunoglobulin (ATG)-Induced T Regulatory Cells and Their Soluble Factors Suppress T Cell Proliferation: Potential Role in Allogeneic Stem Cell Transplantation

Katia Beider, PhD¹^*, David Naor, PhD²^*, Valeria Voevoda¹^*, Olga Ostrovsky, PhD¹^*, Hanna Bitner¹^*, Evgenia Rosenberg¹^*, Nira Bloom, PhD¹^*, Simone Tal¹^*, Ivetta Danilesko, MD¹^*, Avichai Shimoni, MD¹^* and Arnon Nagler, MD, MSc¹

¹Hematology Division, Chaim Sheba Medical Center and Tel Aviv University, Tel-Hashomer, Ramat-Gan, Israel
²Lautenberg Center for Immunology and Cancer Research, Faculty of Medicine, Hebrew University, Jerusalem, Israel

1890

In Vitro Generation of Multi-Epitope Specific CD4⁺ T Helper Cells for Adoptive Immunotherapy of Leukemia

Pawel Muranski¹, Scott Stegemann¹^*, Greg Whitehill, BS²^* and A John Barrett²

¹NHLBI/NIH, Hematology Branch, Bethesda, MD
²Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD

1891

Comprehensive T-Cell Receptor Repertoire Analysis Using Deep Sequencing and Single Cell Cloning Reveals Extreme Oligoclonality of Ex Vivo Expanded Cytomegalovirus-Reactive Cytotoxic T-Cells

Takahiko Miyama, MD¹^*, Takakazu Kawase, MD, PhD¹^*, Kazutaka Kitaura, DVM, PhD²^*, Ren Chishaki³^*, Masashi Shibata³^*, Kumi Oshima, MD, PhD¹^*, Hiroshi Hamana, PhD⁴^*, Hiroyuki Kishi, PhD⁴^*, Kiyotaka Kuzushima, MD, PhD⁵^*, Hiroh Saji, BS⁶^*, Ryuji Suzuki, DVM, PhD⁷^* and Tatsuo Ichinohe, MD¹

¹Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
²Repertoire Genesis Incorporation, ibaraki, Japan
³Hiroshima University, Hiroshima, Japan
⁴Department of Immunology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan
⁵Division of Immunology, Aichi Cancer Center Research Institute, Nagoya, Japan
⁶HLA Laboratory, Kyoto, Japan
⁷Department of Rheumatology and Clinical Immunology, Clinical Research Center for Allergy and Immunology, Sagamihara National Hospital, National Hospital Organization, Sagamihara, Japan

1892

Evaluation of Cytokines after Platelet-Lysate-Expanded Mesenchymal Stromal Cell Therapy for Steroid Refractory Acute Graft-Versus-Host Disease

Yoshiyuki Takahashi, MD, PhD, Daiei Kojima, MD^*, Nozomu Kawashima, MD^*, Norihiro Murakami, MD^*, Kyogo Suzuki, MD^*, Yuko Sekiya, MD^*, Atsushi Narita, MD^*, Michi Kamei, MD, PhD^*, Nobuhiro Nishio, MD, PhD^*, Yusuke Okuno, MD, Ph.D.^*, Hideki Muramatsu, MD, PhD, Asahito Hama, MD, PhD^* and Seiji Kojima, MD, PhD^*

Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan

1893

Manufacturing an Enhanced CAR T Cell Product By Inhibition of the PI3K/Akt Pathway During T Cell Expansion Results in Improved In Vivo Efficacy of Anti-BCMA CAR T Cells

Molly R. Perkins, D.Phil.¹^*, Shannon Grande, Ph.D.¹^*, Amanda Hamel, BS²^*, Holly M. Horton, PhD², Tracy E. Garrett, BA²^*, Sara M. Miller¹^*, Howard J. Latimer IV, BS²^*, Christopher J. Horvath, DVM, MS, DACVP²^*, Michael Kuczewski, MS²^*, Kevin M. Friedman, PhD²^* and Richard A. Morgan, PhD²^*

¹bluebird bio, Cambridge, MA
²bluebird bio, Inc, Cambridge, MA

1894

Ex Vivo Expanded NK Cells Mediate Highly Efficient and Rapid Killing of Ewing Sarcoma Cells Through Degranulation with Tumor Cytotoxicity Controlled by the NKG2D, DNAM-1, and NKp30 NK Receptors

Amrita D. Karambelkar, B.S.^1,2^*, Robert N. Reger, B.S.¹^*, Mattias Carlsten, M.D., Ph.D.¹^* and Richard W. Childs, M.D.¹

¹National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
²Icahn School of Medicine at Mount Sinai, New York, NY

See more of: Adoptive Immunotherapy
See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

703.P1.33 703. Adoptive Immunotherapy: Poster I